



File No. BIO/CT/23/000131

Dated 30-07-2024

To,

M/s. Cliantha Research Limited,
Clantha Corporate, TP 86, FP 28/1, Off S P Ring Road,
Sarkhej Ahmedabad (India) -382210

Subject: Application for grant of permission to conduct Phase- II clinical trial entitled – "A Randomized, Multicenter, Active-controlled Open-labelled, Multiple-Dose, Dose Finding, Parallel Group Trial, Investigating the Efficacy, Safety, Immunogenicity, Tolerability, Pharmacokinetics and Pharmacodynamics of Three Different Weekly Doses of ALT-P1 Compared to Daily Growth Hormone Treatment of GENOTROPIN®(Somatropin) for Injection in Growth Hormone Treatment naive Pre-pubertal Children with Growth Hormone Deficiency" as per Protocol No. C2A03447 Version 2.0 Dated 15.03.2024-regarding.

Ref. No.: Your Application No. BIO/CT04/FF/2023/40197 dated 22.10.2023

Sir,

With reference to your application No.: BIO/CT04/FF/2023/40197 dated 22.10.2023, please find enclosed herewith the permission in Form CT-06 for conduct of subject clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019.

The permission granted by the Central Licensing Authority to conduct clinical trial under this Chapter shall be subject to following conditions, namely:

- (I) You are required to submit the Clinical study report after completion of study.
- (II) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under rule 8
- (III) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:
Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:
Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;
- (IV) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (V) The Central Licensing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;

- (VI) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial.
- (VII) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules.
- (VIII) Status of enrolment of the trial subjects shall be submitted to the Central Licensing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (IX) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licensing Authority electronically in the SUGAM portal.
- (X) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licensing Authority within thirty working days of such termination.
- (XI) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licensing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI.
- (XII) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of the receipt of order issued by Central Licensing Authority in accordance with the provisions of the said Chapter.
- (XIII) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of receipt of the order issued by the Central Licensing Authority in accordance with the provisions of the said Chapter.
- (XIV) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licensing Authority who may be accompanied by officers of the State Licensing Authority or outside experts as authorized by the Central Licensing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial.
- (XV) The laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority.
- (XVI) The Central Licensing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial.
- (XVII) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
- (XVIII) It may kindly be noted that merely granting permission to conduct clinical trial with the drug does not convey or imply that based on the clinical trial data generated with the drug permission to market this drug in the country will automatically be granted to you.

RAJEEV SINGH
RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL
ORGANISATION, ou=CENTRAL DRUGS STANDARD CONTROL
ORGANISATION,
2.5.4.20=RAJEEV SINGH RAGHUVANSHI, email=rajeev.singh@cdsc.gov.in, o=CENTRAL DRUGS STANDARD CONTROL
ORGANISATION, ou=CENTRAL DRUGS STANDARD CONTROL ORGANISATION, serialNumber=657554479490985800304690220e116734c12a1a1
26e994fa5701124a19013, cn=RAJEEV SINGH RAGHUVANSHI
Date: 2024.07.31 10:32:04 +05'30'

Yours faithfully,
Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India)
Licensing Authority

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

The Central Licensing Authority hereby permits M/s. Cliantha Research Limited, Cliantha Corporate, TP 86, FP 28/1, Off S P Ring Road, Sarkhej Ahmedabad (India) - 382210 to conduct Phase-II clinical trial entitled "**A Randomized, Multicenter, Active-controlled Open-labelled, Multiple-Dose, Dose Finding, Parallel Group Trial, Investigating the Efficacy, Safety, Immunogenicity, Tolerability, Pharmacokinetics and Pharmacodynamics of Three Different Weekly Doses of ALT-P1 Compared to Daily Growth Hormone Treatment of GENOTROPIN® (Somatropin) for Injection in Growth Hormone Treatment naive Pre-pubertal Children with Growth Hormone Deficiency**" as per Protocol No. C2A03447 Version 2.0 Dated 15.03.2024 in the below mentioned clinical trial sites.

2. Details of new drug and clinical trial site [as per Annexure].
3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi
Date: 30-JULY-2024

RAJEEV SINGH
RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL
ORGANISATION, ou=CENTRAL DRUGS STANDARD CONTROL
ORGANISATION,
2.5.4.20=42d7189b1c0981bb5a2634a73d025ff4b11b680a91f08
773480400a43ec361b, postalCode=110002, st=Delhi,
serialNumber=657f5e47d940985d8f03bdc902d0e1fe73cfa12a1a
126ea94fa5701124a19013, cn=RAJEEV SINGH RAGHUVANSHI
Date: 2024.07.31 10:32:15 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India)
Central Licensing Authority

Annexure:**Details of new drug or investigational new drug:**

Names of the new drug or investigational new drug:	ALT-P1 30 mg/vial for sub cutaneous injection		
Therapeutic class	Pituitary hormone		
Dosage form:	Drug product contains 30 mg of ALT-P1 drug substance and is filled in a 2 mL glass vial		
Composition:	Each vial contains:		
	Name of Ingredients	Quantity (per vial)	Function
	ALT-P1 drug substance In house	33 mg	Active ingredient
	Sodium phosphate monobasic monohydrate USP	0.044 mg	Buffering agent
	Sodium phosphate dibasic heptahydrate USP	3.85 mg	Buffering agent
	Sodium chloride EP	5.17 mg	Isotonizing agent
	Glycine USP	5.5 mg	Stabilizing agent
	Hydroxypropyl betadex EP	44 mg	Stabilizing agent
	Polysorbate 20 EP	1.21 mg	Stabilizing agent
Water for Injection USP	q.s	Solvent	
Indications:	For the treatment of short stature, growth hormone deficiency		

Details of clinical trial site:

S. No.	Name and Address of Clinical Trial Site	Ethics Committee Details	Name of Principal Investigator
1.	Signus Hospital, 5th Floor, Atlanta Shoppers, Pathardi Road, Pathardi Phata, Nashik 422010, Maharashtra, India	Signus Hospital Ethics Committee Signus Hospital 01, Sai Darshan Bungalow, Prashant Nagar, Pathardi Phata, Nashik, Maharashtra - 422010, India EC Reg No. ECR/1733/Inst/MH/2022	Dr. Chandratreya Sujit Arun
2.	Fortis Hospital, Sector-62, Phase-8, Mohali-160062, Punjab, India	IEC Fortis Hospital Mohali Fortis Hospital Sector - 62, Phase VIII, Mohali, SAS Nagar Punjab - 160062 EC Reg. No.: ECR/28/Inst/PB/2013/RR-19	Dr. Kiran Pal Singh
3.	Sir Ganga Ram Hospital, Sir Ganga Ram Hospital marg, Rajinder Nagar, New Delhi-110060, India	Sir Ganga Ram Hospital Ethics Committee, Sir Ganga Ram Hospital old, Rajinder Nagar, New Delhi-110060 EC Reg. No.:	Dr. Archana D. Arya

		ECR/20/INST/DL/2013/RR-2019	
4.	Manipal Hospital, #98 Old Airport Road, Bengaluru-560017, India	Ethics Committee of Manipal Hospitals, No 98, HAL Airport Road No 98, HAL Airport Road, Bengaluru (Bangalore) Urban Karnataka - 560017 India EC Reg. No.: ECR/34/Inst/KA/2013/RR-19	Dr. Shaila Bhattacharya

